Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores
News

Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores

The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.

  • By IPP Bureau | February 16, 2023
Panacea Biotec Limited has reported total income of Rs. 129.14 crores during the period ended December 31, 2022 as compared to Rs. 115.57 crores during the period ended September 30, 2022.
 
The company has posted net profit of Rs. 19.37 crores for the period ended December 31, 2022 as against net profit of Rs. 15.70 crores for the period ended September 30, 2022.
 
The company has reported EPS of Rs. 3.16 for the period ended December 31, 2022 as compared to Rs. 2.56 for the period ended September 30, 2022.
 
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
 
The company has posted net profit of Rs.19.37 crores for the period ended December 31, 2022 as against net loss of Rs.-49.20 crores for the period ended December 31, 2021.
 
The company has reported EPS of Rs.3.16 for the period ended December 31, 2022 as compared to Rs.-8.03 for the period ended December 31, 2021.
 
The company has reported total income of Rs.367.62 crores during the 9 Months period ended December 31, 2022 as compared to Rs.527.42 crores during the 9 Months period ended December 31, 2021.
 
The company has posted net profit of Rs.-21.07 crores for the 9 Months period ended December 31, 2022 as against net loss of Rs.-159.56 crores for the 9 Months period ended December 31, 2021.
 
The company has reported EPS of Rs.-3.44 for the 9 Months period ended December 31, 2022 as compared to Rs.-26.05 for the 9 Months period ended December 31, 2021.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International